Synaptic regulation of the light-dependent oscillatory currents in starburst amacrine cells of the mouse retina.
Responses of on-center starburst amacrine cells to steady light stimuli were recorded in the dark-adapted mouse retina. The response to spots of dim white light appear to show two components, an initial peak that correspond to the onset of the light stimulus and a series of oscillations that ride on top of the initial peak relaxation. The frequency of oscillations during light stimulation was three time higher than the frequency of spontaneous oscillations recorded in the dark. The light-evoked responses in starburst cells were exclusively dependent on the release of glutamate likely from presynaptic bipolar axon terminals and the binding of glutamate to AMPA/kainate receptors because they were blocked by 6-cyano-7-nitroquinoxalene-2,3-dione. The synaptic pathway responsible for the light responses was blocked by AP4, an agonist of metabotropic glutamate receptors that hyperpolarize on-center bipolar cells on activation. Light responses were inhibited by the calcium channel blockers cadmium ions and nifedipine, suggesting that the release of glutamate was calcium dependent. The oscillatory component of the response was specifically inhibited by blocking the glutamate transporter with d-threo-beta-benzyloxyaspartic acid, suggesting that glutamate reuptake is necessary for the oscillatory release. GABAergic antagonists bicuculline, SR 95531, and picrotoxin increased the amplitude of the initial peak while they inhibit the frequency of oscillations. TTX had a similar effect. Strychnine, the blocker of glycine receptors did not affect the initial peak but strongly decreased the oscillations frequency. These inhibitory inputs onto the bipolar axon terminals shape and synchronize the oscillatory component.
Petit-Jacques
Jerome
J
Department of Physiology and Neuroscience, New York University School of Medicine, 550 First Ave., New York, NY 10016, USA. jpjalpha@yahoo.com
Bloomfield
Stewart A
SA
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D025042:Amacrine Cells / Q000502:physiology*; D000818:Animals; D001224:Aspartic Acid / Q000494:pharmacology; D001683:Biological Clocks / Q000502:physiology*; D019256:Cadmium Chloride / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004558:Electric Stimulation / Q000379:methods; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018684:Glycine Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D008027:Light; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism; D008564:Membrane Potentials / Q000502:physiology / Q000528:radiation effects; D051379:Mice; D008810:Mice, Inbred C57BL; D009543:Nifedipine / Q000494:pharmacology; D018408:Patch-Clamp Techniques / Q000379:methods; D010775:Photic Stimulation / Q000379:methods; D012160:Retina / Q000166:cytology*; D013331:Strychnine / Q000494:pharmacology; D013569:Synapses / Q000502:physiology* / Q000528:radiation effects
D002121:Calcium Channel Blockers; D018691:Excitatory Amino Acid Antagonists; D018684:Glycine Agents; C120673:benzyloxyaspartate; D001224:Aspartic Acid; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; C013411:biocytin; D013331:Strychnine; D009543:Nifedipine; D019256:Cadmium Chloride; D008239:Lysine